MedTrace Logo

CRESTOR Athero Imaging Head to Head IVUS Study

NCT00620542 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 2333

Last updated 2012-07-16

Study results available
· View outcomes & findings →

Summary

A 104-week, randomized, double-blind, parallel group, multi-center Phase IIIb study comparing the effects of treatment with rosuvastatin 40 mg or atorvastatin 80 mg on atherosclerotic disease burden as measured by intravascular ultrasound in patients with coronary artery disease.

Conditions

  • Coronary Atherosclerosis

Interventions

DRUG

Rosuvastatin

capsule, oral, once daily

DRUG

Atorvastatin

capsule, oral, one daily

Sponsors & Collaborators

  • The Cleveland Clinic

    collaborator OTHER

  • AstraZeneca

    lead INDUSTRY

Principal Investigators

  • Stephen J Nicholls, MBBS, PhD · Cleveland Clinic Foundation, Cardiovascular Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2011-06-30
Completion
2011-06-30

Countries

  • United States
  • Argentina
  • Australia
  • Belgium
  • Brazil
  • Canada
  • France
  • Hungary
  • Italy
  • Mexico
  • Netherlands
  • Poland
  • Russia
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00620542 on ClinicalTrials.gov